Voya Investment Management LLC purchased a new stake in SIGA Technologies, Inc. (OTCMKTS:SIGA) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 18,894 shares of the biotechnology company’s stock, valued at approximately $112,000.

Several other hedge funds have also added to or reduced their stakes in SIGA. Renaissance Technologies LLC acquired a new stake in SIGA Technologies during the second quarter worth about $1,158,000. Acuitas Investments LLC grew its stake in SIGA Technologies by 227.0% during the second quarter. Acuitas Investments LLC now owns 468,794 shares of the biotechnology company’s stock worth $2,785,000 after buying an additional 325,410 shares in the last quarter. BlackRock Inc. grew its stake in SIGA Technologies by 35,114.4% during the second quarter. BlackRock Inc. now owns 2,593,187 shares of the biotechnology company’s stock worth $15,403,000 after buying an additional 2,585,823 shares in the last quarter. Schwab Charles Investment Management Inc. acquired a new stake in SIGA Technologies during the second quarter worth about $1,404,000. Finally, Strs Ohio acquired a new stake in SIGA Technologies during the second quarter worth about $295,000. Institutional investors and hedge funds own 6.66% of the company’s stock.

Shares of SIGA Technologies stock opened at $5.07 on Friday. The company has a debt-to-equity ratio of -0.22, a current ratio of 5.49 and a quick ratio of 5.05. SIGA Technologies, Inc. has a 12-month low of $3.90 and a 12-month high of $8.47.

SIGA Technologies (OTCMKTS:SIGA) last announced its quarterly earnings data on Tuesday, August 7th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter. The business had revenue of $2.66 million for the quarter.

About SIGA Technologies

SIGA Technologies, Inc is engaged in the development and commercialization of solutions for various unmet medical needs and biothreats. The Company’s lead product is TPOXX, an orally administered antiviral drug that targets orthopoxviruses infections. TPOXX is a small-molecule drug delivered to the Strategic Stockpile under the Project BioShield Act of 2004 (Project BioShield).

Read More: How to Use the New Google Finance Tool

Want to see what other hedge funds are holding SIGA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SIGA Technologies, Inc. (OTCMKTS:SIGA).

Institutional Ownership by Quarter for SIGA Technologies (OTCMKTS:SIGA)

Receive News & Ratings for SIGA Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SIGA Technologies and related companies with MarketBeat.com's FREE daily email newsletter.